Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Hsp90 inhibitor NVP-BEP800

An orally bioavailable inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor NVP-BEP800 specifically binds to the NH(2)-terminal ATP-binding pocket of Hsp90 and specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival, including ErbB2, B-Raf(V600E), Raf-1, and Akt. This prevents oncogenic pathway signaling mediated by these proteins and leads to the inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.
Synonym:heat shock protein 90 inhibitor NVP-BEP800
Code name:NVP BEP800
NVP-BEP800
NVPBEP800
Search NCI's Drug Dictionary